Assenagon Asset Management S.A. grew its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 52.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 25,936 shares of the medical equipment provider's stock after purchasing an additional 8,959 shares during the period. Assenagon Asset Management S.A.'s holdings in Lantheus were worth $2,320,000 as of its most recent filing with the SEC.
Several other large investors have also recently added to or reduced their stakes in LNTH. Signaturefd LLC increased its stake in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 92 shares in the last quarter. UMB Bank n.a. raised its position in shares of Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock valued at $47,000 after acquiring an additional 126 shares during the period. GAMMA Investing LLC boosted its stake in Lantheus by 45.5% during the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock worth $51,000 after acquiring an additional 146 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Lantheus during the third quarter valued at approximately $25,000. Finally, CWM LLC increased its stake in Lantheus by 63.0% in the third quarter. CWM LLC now owns 750 shares of the medical equipment provider's stock valued at $82,000 after purchasing an additional 290 shares in the last quarter. 99.06% of the stock is owned by institutional investors.
A number of equities analysts have recently weighed in on LNTH shares. JMP Securities reissued a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. StockNews.com lowered shares of Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Truist Financial reaffirmed a "buy" rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, The Goldman Sachs Group started coverage on Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $131.86.
Get Our Latest Research Report on LNTH
Shares of LNTH opened at $95.39 on Thursday. The company has a market cap of $6.63 billion, a PE ratio of 15.87 and a beta of 0.46. The firm has a 50-day moving average of $90.36 and a 200-day moving average of $100.29. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89.
In other news, Director James H. Thrall sold 1,000 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.10% of the stock is currently owned by corporate insiders.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Lantheus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantheus wasn't on the list.
While Lantheus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.